May 3, 2018
Authored and Edited by Paula E. Miller; Shana K. Cyr, Ph.D.
On April 27, 2018, FDA issued draft guidance on Multiple Function Device Products: Policy and Considerations. A multiple function device product contains at least one device function and at least one other function. The guidance clarifies when and how FDA intends to assess the impact of other functions of a medical device that are not the subject of a premarket review on the safety and effectiveness. This guidance stems from the medical software section of the 21st Century Cures Act and is part of the FDA’s long-term Digital Health Innovation Action Plan.
The term “function” is a distinct purpose of the medical device, which could be the intended use or a subset of the intended use of the product. For products containing multiple functions, FDA identifies “other functions” as those that:
In the sponsor’s premarket review submission, FDA recommends separating the device function under FDA’s review from other functions of the device, where possible, because it is easier it is for FDA to independently review the device function. FDA recommends that the sponsor evaluate whether the other function may impact the safety or effectiveness of the device function. And if so, the sponsor should also determine if the impact could result in an increased risk or an adverse effect on performance due to the combination of the other function with the device function-under-review. The guidance identifies additional documentation the sponsor should include in the premarket submission to address any potential adverse impact, or any positive impact that the sponsor would like FDA to consider, including any risk mitigation steps to avoid the potential adverse impact. Where the device function is not adversely impacted by the other function, FDA does not intend to assess that other function in the premarket review.
One example provided by FDA is a smartphone app that would use the camera to take a picture of a suspicious lesion and analyze the photograph to detect skin cancer. The multiple functions would be the device function “analyze” and the other function “take picture.” FDA recommends the premarket submission include documentation to show the evaluation of a potential for an adverse impact between the two different functions. The documentation should detail, for example, the risk mitigation such as error handling to determine if the picture is not adequate for detecting skin cancer, which could result in misdiagnosis. FDA would review the “analyze” function of the app for safety and effectiveness but would likely not review the camera or the smartphone platform.
Readers are encouraged to read the draft guidance, also available on FDA’s website. Comments and suggestions regarding the draft guidance should be submitted to FDA by June 26, 2018.
Food and Drug Administration (FDA), FDA Guidance, combination product, new drug application (NDA)
Copyright © 2018 Finnegan, Henderson, Farabow, Garrett & Dunner, LLP.
DISCLAIMER: Although we wish to hear from you, information exchanged in this blog cannot and does not create an attorney-client relationship. Please do not post any information that you consider to be personal or confidential. If you wish for Finnegan, Henderson, Farabow, Garrett & Dunner, LLP to consider representing you, in order to establish an attorney-client relationship you must first enter a written representation agreement with Finnegan. Contact us for additional information. One of our lawyers will be happy to discuss the possibility of representation with you. Additional disclaimer information.
Conference
2024 Licensing Executives Society USA – Canada Annual Meeting
October 20-23, 2024
New Orleans
Conference
4th Annual Passport to Proficiency on the Essentials of Hatch-Waxman and BPCIA
October 8-24, 2024
Virtual
Webinar
September 10, 2024
Webinar
Due to international data regulations, we’ve updated our privacy policy. Click here to read our privacy policy in full.
We use cookies on this website to provide you with the best user experience. By accepting cookies, you agree to our use of cookies. Please note that if you opt not to accept or if you disable cookies, the “Your Finnegan” feature on this website will be disabled as well. For more information on how we use cookies, please see our Privacy Policy.
Finnegan is thrilled to announce the launch of our new blog, Ad Law Buzz, devoted solely to breaking news, developments, trends, and analysis in advertising law.